Drugs / Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
also known as
MAGE-A3-01
Cell therapy targets MAGEA3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02153905 | Jul 2014 → Sep 2018 | breast cancer, cervical cancer, kidney cancer, melanoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR) | “Biological: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)” NCT02153905 ↗ |
| Known as | MAGE-A3-01 | “Determine a safe dose of administration of autologous T cells transduced with an anti- MAGE-A3 HLA-A 01-restricted TCR (MAGE-A3-01) TCR and aldesleukin” NCT02153905 ↗ |
| Modality | Cell therapy | “TCR gene-transduced PBMC” NCT02153905 ↗ |
| Route | Intravenous | “MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously” NCT02153905 ↗ |
| Target | MAGEA3 | “MAGE-A3 tumor antigen” NCT02153905 ↗ |